Target baby food recalled due to possible elevated levels of lead
A company that makes baby food sold under a Target store brand is recalling more than 25,000 packages of a product because it may contain elevated levels of lead.
Miami-based Fruselva issued the recall in March for Target's Good & Gather Baby Pea, Zucchini, Kale & Thyme Vegetable Puree, sold in 4-ounce tubs, according to the U.S. Food and Drug Administration.
The packages include lot number 4167, with a best-by date of Dec. 7, and lot number 4169, with a best-by date of Dec. 9.
Consumers should not feed babies the products.
The recall is listed as Class II, which means the products are unlikely to cause serious harm, but still have the potential to result in temporary or reversible problems.
There is
no safe level of exposure to lead for children
, according to the U.S. Centers for Disease Control and Prevention. Exposure to the heavy metal can cause developmental and cognitive problems. Babies, children under 6 years old and pregnant women are at the highest risk when exposed to lead.
Earlier this month, Johnsonville recalled
over 22,600 pounds of cheddar bratwurst
in several states, including Minnesota and Wisconsin.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
8 ice cream flavors recalled in Ohio
WAUSEON, Ohio — An Ohio-based creamery has announced a voluntary recall due to undeclared allergens in eight of their ice cream flavors. According to the Ohio Department of Agriculture, Turkeyfoot Creek Creamery of Wauseon, Ohio, is recalling the following flavors of ice cream; Avalanche, Chocolate Peanut Butter, Chocolate Strawberry, Chocolate Brownie Bites, Cookies and Cream, Cookie Dough, Cacao and Mocha. Massive egg recall hits Ohio Walmart stores The affected products are all packaged in pint containers and were distributed to six stores, located in Canton, Cleveland, West Unity, and Arlington, Ohio. As well, as two stores located out of state, with one in Fort Wayne, Indiana, and the other in Hudson, Michigan, read a press release from the Ohio Department of Agriculture. Young mother killed in shooting at Cleveland Metroparks Mill Creek Falls 'There have been no reports of illness involving products addressed in this recall, however, individuals exhibiting signs or symptoms of an allergic reaction after consuming Turkeyfoot Creek Creamery Ice Cream involved in this recall should contact a physician immediately,' stated the release. All affected products have been removed from store shelves. Consumers can return recalled products to the place of purchase for a refund. Consumers with questions can call 419-583-7124. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Topeka's KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer
BURR RIDGE, Ill., June 11, 2025 /PRNewswire/ -- SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure Experience™, today announced its first availability in Kansas at an event at Topeka's KMC Dermatology. Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinoma) that uses ultrasound imaging to help clinicians direct low-level x-rays to targeted areas of the skin, killing cancer cells. For patients treated with Image-Guided SRT, the cure rate (freedom from recurrence at six years) has been shown to be greater than 99 percent, with researchers reporting that for appropriately selected early-stage nonmelanoma skin cancers, Image-Guided SRT is a clinically equivalent alternative to Mohs surgery and statistically significant in superiority to non-Image-Guided SRT. Dr. Joseph Gadzia of KMC Derm noted, "More than 26,000 individuals in Kansas are expected to be diagnosed with nonmelanoma skin cancer this year. We know that sun exposure is the main cause of this type of cancer but there are other factors as well. For those who have been diagnosed with nonmelanoma skin cancer, we now offer a nonsurgical treatment option which we call the GentleCure Experience, and we are proud to be the first practice in the state to offer it." Dr. Gadzia also added, "While most common skin cancers have been treated with Mohs surgery, this newer treatment option achieves close to the same success rate with no surgery, no surgical scarring, and no bleeding. As of this past April, more than 100,000 patients have been successfully treated with Image-Guided SRT in the United States." Other speakers included Dr. Shekhar Challa; U.S. Senator Roger Marshall via video; Topeka Mayor Michael Padilla; Aaron Mays, Chairman of the Shawnee County Board of Commissioners; and John Mugler, District Director, Office of Senator Marshall. In addition, Kansas Governor Laura Kelly issued a gubernatorial proclamation declaring June 8 – 14 "Kansas Nonmelanoma Skin Cancer Awareness Week," noting that KMC Dermatology is the first practice in the state of Kansas to offer Image-Guided SRT. Kerwin Brandt, chief executive officer of Chicago-based SkinCure Oncology, said, "We are delighted to partner with KMC Dermatology to offer this highly effective, noninvasive treatment option for their patients. It is critical that patients everywhere have the choice of treating their nonmelanoma skin cancer without surgery." About SkinCure OncologySkinCure Oncology is the industry leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure Experience™, Image-Guided SRT is available from some 500 physicians nationwide, with more than 100,000 patients having been treated. Learn more about the company at and visit for helpful consumer and patient information. Media Contact:Matt RussellRussell Public Communications520-232-9840mrussell@ View original content to download multimedia: SOURCE SkinCure Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Texas to expand psychedelic research with $50M ibogaine investment
AUSTIN (KXAN) — Texas Gov. Greg Abbott is holding a bill signing ceremony Tuesday for legislation that invests $50 million into clinical research of ibogaine — a naturally occurring psychedelic substance that could treat post-traumatic stress disorder, opioid use disorder and other mental health conditions. For years, veterans and others suffering from PTSD have sought ibogaine treatment in Mexico, where the substance is not heavily regulated. In the United States, ibogaine is classified as a Schedule 1 drug, the most restrictive drug category. Other drugs classified under Schedule 1 include psilocybin, LSD and heroin. According to the legislative summary of SB 2308, the implications for those with opioid use disorder are lifechanging; a single administration of ibogaine in a controlled setting has been shown to stop withdrawal symptoms and reduce drug cravings long-term. RELATED: Lawmakers hope to expand medical marijuana program as state bans intoxicating hemp products 'Preliminary reports also suggest benefits in cognitive function, mood regulation, and sleep among individuals with [traumatic brain injury] and PTSD—conditions prevalent among U.S. veterans,' the bill text read. The new legislation will create a program within the Texas Health and Human Services Commission to support Texas-based trials of ibogaine through the FDA. Ibogaine is not currently FDA-approved due to its Schedule 1 classification. SB 2308 will fund research through gifts, grants or donations and will require equal matching funds by the recipients, which will include Texas medical facilities 'equipped for cardiac-intensive monitoring' by a supervising physician, among other qualifications. 'By advancing ibogaine research, Texas has the opportunity to lead in neuroscience innovation, address urgent veteran health needs, and shape the future of mental health treatment nationwide,' the bill text reads. While legislation aimed at easing access to ibogaine moves forward, separate legislation to restrict access to another plant has also progressed. Texas lawmakers sent a bill banning non-medical THC products to Abbott for approval late last month. Still, Texas in recent years has become more open-minded to the use of psychedelic substances in treating mental health conditions. 'There's definitely been a shift in the openness and the receptivity of the field to this type of research,' said Greg Fonzo, Ph.D., co-director of the McGill Center for Psychedelic Research & Therapy at Dell Medical School. 'People who do undergo this treatment process, some of them respond well and have a benefit in terms of symptom reductions and feeling better,' Fonzo told KXAN earlier this year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
